The research interests of Grant D. Schmit, M.D., include diagnostic imaging of the abdomen using computerized tomography (CT), magnetic resonance imaging (MRI) and ultrasound, and nonvascular image-guided interventional procedures. Dr. Schmit's primary research focus is on percutaneous ablation of malignancies in the kidneys, liver, lungs and bones.
- Skeletal muscle CT. Dr. Schmit is a co-investigator on a Mayo Clinic study using quantitative determination of patient skeletal muscle from CT scans as a predictor of outcomes after surgery and other medical interventions.
- Imaging for liver cancer diagnoses. Dr. Schmit contributed to a prospective, multicenter comparison of multiphase, contrast-enhanced CT and MRI for the diagnosis of hepatocellular carcinoma and liver transplant allocation.
- Ablation of liver cancer. Dr. Schmit served as the principal investigator for Mayo Clinic on a multicenter clinical trial investigating the efficacy and safety of ThermoDox, a thermally sensitive liposomal doxorubicin, with radiofrequency ablation as a therapy for inoperable liver cancer (nonresectable hepatocellular carcinoma).
Significance to patient care
Dr. Schmit's ultimate research goal is to optimize percutaneous ablation methods and improve outcomes for patients with cancer in the kidneys, liver, lungs and bones.
- Bronze level certification, Mayo Quality Fellows, Mayo Clinic, 2012